博雅生物(300294) - 2023年11月1日投资者关系活动记录表

Financial Performance - The company achieved a total operating revenue of 2.19 billion CNY in the first three quarters of 2023, representing a year-on-year growth of 5.17% [2] - The net profit after deducting non-recurring gains and losses was 361 million CNY, with a year-on-year increase of 1.48% [2] - Blood products business generated an operating revenue of 1.085 billion CNY, showing a year-on-year growth of 4.82% [2] - The third quarter revenue was 649 million CNY, a year-on-year decline of 5.04% [2] - The net profit for the third quarter was 104 million CNY, down 4.20% year-on-year [2] Plasma Collection and Business Development - From January to October 2023, the company collected a total of 385 tons of raw plasma, marking a year-on-year increase of 3.4% [3] - Measures to enhance plasma collection include optimizing existing plasma stations and constructing new ones [3] - The company plans to complete the construction of new plasma stations in Taihe County and LePing City by May 2024 [3] Product Development and Market Strategy - The company’s PCC market share exceeds 15%, with expectations for further growth through academic promotion [4] - The company is advancing the development of several blood products, including vWF factor and high-concentration immunoglobulin, with expected market launches within three years [4] - The demand for blood products is anticipated to grow due to an aging population and increasing needs in developing countries [4] Financial Strategy and Future Planning - Future major expenditures will focus on the construction of smart factories and new plasma stations [5] - The company plans to implement a suitable dividend policy based on operational performance and financial status [6] - The company is exploring internationalization strategies, including product exports and technology cooperation [6] Goodwill and Asset Management - The company’s goodwill, primarily from acquisitions, totals 660 million CNY, with ongoing assessments for impairment [6] - The company is considering stock incentive plans in line with government policies, contingent on business conditions [6]